AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02709577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Description: The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
Study NCT02709577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: endoscopy and standard of care
Description: Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
Study NCT00333411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX
Study NCT00333411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01642056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
Study NCT01642056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EPI-743
Description: This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
Study NCT01642056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.
Study NCT02468960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Predilatation with OPN NC balloon catheter.
Description: Target lesion will be prepared by predilatation with OPN NC balloon catheter.
Study NCT02468960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Predilatation with standard compliant balloon.
Description: Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
Study NCT01642056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02468960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Absorb BVS implantation.
Description: After lesion preparation implantation of BVS Absorb scaffold will be performed.
Study NCT01230190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ecologic ® Panda II
Description: Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals.
Study NCT01230190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
Study NCT01689987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01689987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01689987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT02468960 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treated segment visualization by OCT.
Description: Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
Study NCT02468960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical FU at 12 months.
Description: All patients will be clinically followed for 12 months.
Study NCT01689987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01854489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
Study NCT01854489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
Study NCT01854489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
Study NCT02476344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiment protocol
Description: each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously.
Study NCT01689987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01689987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study NCT02669394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
Study NCT02669394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: stretching and relaxation program
Description: Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
Study NCT01875393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD® Soluble
Description: The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
Study NCT03569787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Pituitary
Description: Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
Study NCT03757624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shrinkage
Description: shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
Study NCT03376139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
Study NCT03376139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
Study NCT01413295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Study NCT01478178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083 (Dianhydrogalactitol)
Description: VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
Study NCT00326157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
Study NCT03271307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized PITC
Description: Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
Study NCT03271307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Facility HIVST
Description: HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
Study NCT03271307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Index HIVST
Description: HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
Study NCT02784977 — intervention group
Intervention type: DEVICE
Intervention: Positive Airway Pressure (PAP)
Description: Treatment of OSA with PAP
Study NCT02784977 — intervention group
Intervention type: DEVICE
Intervention: Intraoral device (IOD)
Description: Treatment of OSA with IOD
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.
Study NCT02784977 — intervention group
Intervention type: PROCEDURE
Intervention: Uvuloplasty
Description: Uvuloplasty
Study NCT02784977 — intervention group
Intervention type: OTHER
Intervention: Conservative treatment
Description: No active intervention
Study NCT01721512 — intervention group
Intervention type: OTHER
Intervention: Breastfeeding
Study NCT01721512 — intervention group
Intervention type: OTHER
Intervention: Infant formula
Study NCT04686877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STAPLE
Description: Stereotactic aspiration plus urokinase clot irrigation
Study NCT01413295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive treatment
Description: Supportive treatment after progression of the illness after 2 lines of chemotherapy
Study NCT01279291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KHK2866
Description: Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study NCT01279291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age.
Study NCT01279291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
Study NCT01279291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
Study NCT00740454 — intervention group
Intervention type: OTHER
Intervention: Lower limb veins compression ultrasonography
Description: Distal and proximal lower limb veins compression ultrasonography
Study NCT00651014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Study NCT00651014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Study NCT04022525 — intervention group
Intervention type: DRUG
Intervention: Leflunomide 20Mg Tab
Description: blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
Study NCT01290146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics
Description: Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
Study NCT01290146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min
Study NCT00708747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin (5% serum-protein solution containing immunoglobulins)
Description: 5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
Study NCT00708747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biseko
Description: Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
Study NCT02020798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 12.5 mg ABT-869
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-869
Description: Placebo Comparator (12.5 mg or 7.5 mg)
Study NCT03345355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 7.5 mg ABT-869
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6 mg/mL/min)
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC 6 mg/mL/min)
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2)
Study NCT00716534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2)
Study NCT03256643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
Study NCT03256643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Exercise
Description: People will be tested up to 40 weeks after beginning the intervention.
Study NCT03256643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and enrichment
Description: Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
Study NCT05152030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 'TIB' Olfactory Test
Description: A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
Study NCT04312477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study NCT04312477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study NCT00302744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (drug)
Description: Capsule (.2 mg/kg).
Study NCT00302744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Active Placebo
Study NCT00302744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI required for study inclusion for purpose of ruling out metasteses to brain
Study NCT00302744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI required for study inclusion for purpose of ruling out metasteses to brain
Study NCT02229708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Group
Study NCT03469622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings
Description: EndoRings-assisted colonoscopy
Study NCT03469622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy without any additional devices
Study NCT01163305 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Study NCT02648009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized (13) Pyruvate Injection
Description: MRI with Hyperpolarized Pyruvate (13) Injection
Study NCT02648009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadolinium
Description: MRI with Gadolinium
Study NCT04212078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic
Description: 0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
Study NCT04212078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
Study NCT00792740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
Study NCT00792740 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
Study NCT00556439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept.